High-mobility group box 1: A novel target for treatment of Pseudomonas aeruginosa keratitis

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1776-1787

  McClellan, Sharon ^a   Jiang, Xiaoyu ^a   Barrett, Ronald ^a   Hazlett, Linda D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; HMGB1 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ADVANCED GLYCATION END PRODUCT RECEPTOR GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL KERATITIS; CELL INFILTRATION; CONTROLLED STUDY; CXCL12 GENE; CXCR4 GENE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; INTERLEUKIN 1BETA GENE; MACROPHAGE INFLAMMATORY PROTEIN 2 GENE; MOUSE; NONHUMAN; PSEUDOMONAS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGIRR GENE; SIGNAL TRANSDUCTION; ST2 GENE; TOLL LIKE RECEPTOR 4 GENE; TUMOR NECROSIS FACTOR ALPHA GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIAL EYE INFECTION; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KERATITIS; METABOLISM; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE INFECTIONS, BACTERIAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; KERATITIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84922572953     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401684     Document Type: Article

References (43)

1. Wilhelmus, K. R. 1987. Review of clinical experience with microbial keratitis associated with contact lenses. CLAO J. 13: 211-214.
2. Hazlett, L. D. 2004. Corneal response to Pseudomonas aeruginosa infection. Prog. Retin. Eye Res. 23: 1-30.
3. Moon, M. M., L. D. Hazlett, R. E. Hancock, R. S. Berk, and R. Barrett. 1988. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. Invest. Ophthalmol. Vis. Sci. 29: 1277-1284.
4. Steuhl, K.-P., G. Döring, A. Henni, H.-J. Thiel, and K. Botzenhart. 1987. Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections. Invest. Ophthalmol. Vis. Sci. 28: 1559-1568.
5. Thiel, H.-J., K. P. Steuhl, and G. Döring. 1987. Therapy of Pseudomonas aeruginosa eye infections. Antibiot Chemother (1971) 39: 92-101.
6. Hazlett, L. D., D. D. Rosen, and R. S. Berk. 1977. Experimental Pseudomonas keratitis in immunosuppressed hybrid mice. Ophthalmic Res. 9: 374-380.
7. Chusid, M. J., and S. D. Davis. 1979. Experimental bacterial keratitis in neu-tropenic guinea pigs: polymorphonuclear leukocytes in corneal host defense. Infect. Immun. 24: 948-952.
8. Rudner, X. L., K. A. Kernacki, R. P. Barrett, and L. D. Hazlett. 2000. Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation. J. Immunol. 164: 6576-6582.
9. Kernacki, K. A., R. P. Barrett, J. A. Hobden, and L. D. Hazlett. 2000. Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection. J. Immunol. 164: 1037-1045.
10. Szliter, E. A., S. Lighvani, R. P. Barrett, and L. D. Hazlett. 2007. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J. Immunol. 178: 1105-1114.
11. Jiang, X., S. A. McClellan, R. P. Barrett, Y. Zhang, and L. D. Hazlett. 2012. Vasoactive intestinal peptide downregulates proinflammatory TLRs while upreg-ulating anti-inflammatory TLRs in the infected cornea. J. Immunol. 189: 269-278.
12. Chorny, A., and M. Delgado. 2008. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am. J. Pathol. 172: 1297-1307.
13. Wu, D., D. Lee, and Y. K. Sung. 2011. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir. Res. 12: 45.
14. Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H. E. Harris, S. M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101: 296-301.
15. Liu, K., S. Mori, H. K. Takahashi, Y. Tomono, H. Wake, T. Kanke, Y. Sato, N. Hiraga, N. Adachi, T. Yoshino, and M. Nishibori. 2007. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 21: 3904-3916.
16. Kwon, B., and L. D. Hazlett. 1997. Association of CD4+ T cell-dependent keratitis with genetic susceptibility to Pseudomonas aeruginosa ocular infection. J. Immunol. 159: 6283-6290.
17. Hazlett, L. D., M. M. Moon, M. Strejc, and R. S. Berk. 1987. Evidence for N-acetylmannosamine as an ocular receptor for P. aeruginosa adherence to scarified cornea. Invest. Ophthalmol. Vis. Sci. 28: 1978-1985.
18. Huang, X., R. P. Barrett, S. A. McClellan, and L. D. Hazlett. 2005. Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 46: 4209-4216.
19. Kleinman, M. E., K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J. Z. Baffi, R. J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
20. Heid, C. A., J. Stevens, K. J. Livak, and P. M. Williams. 1996. Real time quantitative PCR. Genome Res. 6: 986-994.
21. Williams, R. N., C. A. Paterson, K. E. Eakins, and P. Bhattacherjee. 1982-1983. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr. Eye Res. 2: 465-470.
22. Wang, H., S. Zhu, R. Zhou, W. Lei, and A. E. Sama. 2008. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10: e32. doi:10.1017/S1462399408000884.
23. Morice, A., R. J. Unwin, and P. S. Sever. 1983. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchocon-striction in asthmatic subjects. Lancet 2: 1225-1227.
24. Jiang, X., S. A. McClellan, R. P. Barrett, Y. Zhang, M. E. Foldenauer, and L. D. Hazlett. 2012. The role of VIP in cornea. Invest. Ophthalmol. Vis. Sci. 53: 7560-7566.
25. Wang, H., O. Bloom, M. Zhang, J. M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
26. Gardella, S., C. Andrei, D. Ferrera, L. V. Lotti, M. R. Torrisi, M. E. Bianchi, and A. Rubartelli. 2002. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3: 995-1001.
27. Andersson, U., and K. J. Tracey. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29: 139-162.
28. Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, M. Rosas-Ballina, C. J. Czura, J. M. Huston, E. Miller, et al. 2006. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203: 1637-1642.
29. Keyel, P. A. 2014. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine 69: 136-145.
30. Yanai, H., A. Matsuda, J. An, R. Koshiba, J. Nishio, H. Negishi, H. Ikushima, T. Onoe, H. Ohdan, N. Yoshida, and T. Taniguchi. 2013. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. USA 110: 20699-20704.
31. Entezari, M., D. J. Weiss, R. Sitapara, L. Whittaker, M. J. Wargo, J. Li, H. Wang, H. Yang, L. Sharma, B. D. Phan, et al. 2012. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol. Med. 18: 477-485.
32. Bianchi, M. E. 2009. HMGB1 loves company. J. Leukoc. Biol. 86: 573-576.
33. Rouhiainen, A., J. Kuja-Panula, E. Wilkman, J. Pakkanen, J. Stenfors, R. K. Tuominen, M. Lepäntalo, O. Carpén, J. Parkkinen, and H. Rauvala. 2004. Regulation of monocyte migration by amphoterin (HMGB1). Blood 104: 1174-1182.
34. Yang, D., Q. Chen, H. Yang, K. J. Tracey, M. Bustin, and J. J. Oppenheim. 2007. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81: 59-66.
35. Dumitriu, I. E., M. E. Bianchi, M. Bacci, A. A. Manfredi, and P. Rovere-Querini. 2007. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81: 84-91.
36. Orlova, V. V., E. Y. Choi, C. Xie, E. Chavakis, A. Bierhaus, E. Ihanus, C. M. Ballantyne, C. G. Gahmberg, M. E. Bianchi, P. P. Nawroth, and T. Chavakis. 2007. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26: 1129-1139.
37. Degryse, B., T. Bonaldi, P. Scaffidi, S. Müller, M. Resnati, F. Sanvito, G. Arrigoni, and M. E. Bianchi. 2001. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152: 1197-1206.
38. Degryse, B., and M. de Virgilio. 2003. The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 553: 11-17.
39. Penzo, M., R. Molteni, T. Suda, S. Samaniego, A. Raucci, D. M. Habiel, F. Miller, H. P. Jiang, J. Li, R. Pardi, et al. 2010. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated che-motaxis [corrected]. J. Immunol. 184: 4497-4509.
40. Schiraldi, M., A. Raucci, L. M. Muñoz, E. Livoti, B. Celona, E. Venereau, T. Apuzzo, F. De Marchis, M. Pedotti, A. Bachi, et al. 2012. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209: 551-563.
41. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, et al; AMD3100 HIV Study Group. 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37: 1253-1262.
42. Zhang, F., G. Huang, B. Hu, L. P. Fang, E. H. Cao, X. F. Xin, Y. Song, and Y. Shi. 2014. Anti-HMGB1 neutralizing antibody ameliorates neutrophilic airway inflammation by suppressing dendritic cell-mediated Th17 polarization. Mediators Inflamm. 2014: 257930.
43. Limana, F., G. Esposito, P. Fasanaro, E. Foglio, D. Arcelli, C. Voellenkle, A. Di Carlo, D. Avitabile, F. Martelli, M. A. Russo, et al. 2013. Transcriptional profiling of HMGB1-induced myocardial repair identifies a key role for Notch signaling. Mol. Ther. 21: 1841-1851.